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BACKGROUND: Progesterone creams and natural or
bioidentical compounded estrogen preparations are
being promoted to consumers as safe alternatives to con-
ventional menopausal hormone therapy and as health-
promoting tonics. No reliable data support these claims.
SAFETY: Natural hormones, including estradiol, estri-
ol, estrone, and progesterone, can be expected to have
the same adverse event profile as conventional meno-
pausal hormone regimens.
SALIVARY HORMONE TESTS: Salivary tests may be
used to persuade asymptomatic consumers to use
hormones (or symptomatic patients to use higher doses
than those needed to mitigate symptoms), a practice
that can be expected to result in adverse events.
KEY WORDS: natural hormones; bioidentical hormones; menopausal
hormone therapy; topical progesterone cream; estriol; compounding
pharmacies; Triest; salivary hormone testing.
DOI: 10.1007/s11606-007-0141-4
© 2007 Society of General Internal Medicine 2007;22:1030–1034
B ioidentical or natural hormones are being promoted toconsumers as benign health tonics. The term bioiden-
tical is a pseudoscientific neologism that refers to endogenous
hormones, including estriol, estrone, estradiol, progesterone,
testosterone, DHEA, thyroxine, and cortisol. Natural alludes to
the fact that these are native human hormones. In fact, these
hormones are synthesized or semisynthesized. Stigmasterol
from soybeans (Glycine max) and diosgenin from an inedible
Mexican yam (Dioscorea villosa) can be converted to progester-
one in the laboratory,1 but there is no evidence that plant
sterols convert to progesterone endogenously.
Many bioidentical hormone products that require a pre-
scription are prepared by compounding pharmacies. Com-
pounding pharmacies use commercially available drugs to
create formulations that are not commercially available. For
example, compounding pharmacies routinely turn tablets into
syrup for patients with swallowing problems, combine two or
three pills into a single capsule, make a pet-sized dose of a
drug meant for humans, or make a topical preparation from a
drug available only in an oral form. Because compounding
pharmacies are not manufacturing facilities, they are not
subject to FDA standards for good manufacturing practices.
Compounded preparations are not regulated by the FDA and
may vary in potency. For example, one study found that only 1
of 10 compounding pharmacies provided progesterone vaginal
suppositories that were all within the potency range required
of similar FDA-approved products.2
This article will focus on compounded bioidentical hormone
preparations aimed at menopausal and perimenopausal wom-
en. Oral products include estriol, biestrogen (Bi-est, containing
20% estradiol and 80% estriol), or triestrogen (Tri-est, contain-
ing 10% estrone, 10% estradiol, and 80% estriol). Estriol is
usually dosed at 2mg twice daily; the usual dose of Bi-est or Tri-
est is 1.25–2.5 mg twice daily. These doses are believed to be
equivalent to 0.625–1.25 mg of conjugated equine estrogens.
The term estrogens encompasses all forms, including human
estrogens (estradiol, estriol, and estrone), synthetic forms (for
example, ethinyl estradiol), and conjugated equine estrogens
(mixed estrogens derived from mare’s urine). The term proges-
togen is an umbrella term that encompasses progesterone,
which is the mammalian progestogen, and synthetic progestins
(for example, medroxyprogesterone). Bioidentical progesterone
is micronized progesterone, oral forms of which are used in
conventional medicine. Transdermal progesterone cream, how-
ever, remains an alternative treatment in the United States.
Although all oral hormonal preparations require a prescrip-
tion, topical hormone preparations are generally regulated as
cosmetics, not drugs,3 and so are readily available without a
prescription. Health food stores sell progesterone and DHEA
creams, and estrogen creamsmay be purchased on the internet.
HEALTH CLAIMS
Estrogen is an effective treatment for hot flashes and vaginal
dryness, but neither estrogen nor estrogen/progestin therapy
should be used for disease prevention. Natural hormone
proponents, however, claim that bioidentical hormones are
different than conventional hormone regimens and will prevent
disease. An educational packet distributed by one compound-
ing pharmacy claims that “there are cardiovascular benefits to
hormone therapy...protecting against premature heart disease,
hypertension, and cholesterol.”4 Another pharmacy states that
their hormone therapy protects against heart disease, breast
cancer, and endometrial cancer.5 A company that sells various
hormones over the internet describes estrogen as “literally a
heart saver.”6 And another pharmacy states that Bi-est “...
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might allow for all of the protection of estriol, while potentially
providing the cardiovascular and osteoporosis benefits and
vasomotor symptom relief of estradiol.”7
Although estrogen or estrogen–progestogen combinations
are far more common, oral or injected progestogens are
occasionally used in conventional medicine to treat hot flashes.
Transdermal progesterone cream has also been tested for
hot flashes; one study found a positive effect8 and another
found no effect.9 Progesterone cream is promoted to treat and
prevent osteoporosis, and as a general health tonic. However,
no clinical trials support the use of progesterone cream for
either of these claims.
The perception that progesterone cream is a panacea can be
traced to the late John M. Lee, MD, whose popular books
claimed that breast cancer, fibroids, fibrocystic breasts, pre-
menstrual syndrome, osteoporosis, and other conditions were
all linked to “estrogen dominance secondary to relative insuf-
ficiency of progesterone.”10–13 One web site that sells proges-
terone cream states that “Natural progesterone cream contains
NO synthetic hormones and thus can help you balance your
hormones, eliminate estrogen dominance and relieve your
symptoms without dangerous side effects.”14 Another web site
claims, “Natural progesterone should not be confused with the
progestins or progestogens in birth control pills and other
drugs... Natural, USP progesterone, on the other hand, is
identical to the body’s own progesterone molecule, and has no
serious side effects when used as directed.”15
Popular books have contributed to misconceptions about
hormones. Actress Suzanne Somers has published three books
promoting bioidentical hormone therapy in 3 years. In her latest
book, Ageless: the Naked Truth About Bioidentical Hormones,
Somers states, “Hormones are our life force; the decline of
hormones is the hallmark of aging;” “Without hormone replace-
ment, we will end up mere shells of our former selves;” and
“Disease doesn’t develop when hormones are in perfect bal-
ance.”16 Despite developing breast cancer and undergoing a
hysterectomy for endometrial hyperplasia while taking bioiden-
tical hormones, Somers remains a hormone enthusiast.
Several physicians promote these hormones. Erica Schwartz,
MD, author of The Hormone Solution: Naturally Alleviate
Symptoms of Hormone Imbalance from Adolescence Through
Menopause (NY: Warner Books; 2002) and The 30-Day Natural
Hormone Plan: Look and Feel Young Again—Without Synthetic
HRT (NY: Warner Books; 2004) evaluates patients through
telephone interviews and prescribes hormone treatment.
Schwartz states on her web site, “‘Natural’ Bio Identical
Hormones are exactly the same as the hormones your body
made when you were younger except they don’t have the same
adverse side effects commonly associated with ‘Synthetic’
Hormone Replacement Therapy. ”17
Steven F. Hotze, MD, author of Hormones, Health, and
Happiness (Houston, Tex, USA: Forrest Publishers; 2005) and
proprietor of the Hotze Health and Wellness Center in Hous-
ton, Tex, USA claims that, “When our hormones are in balance
we are young, healthy, radiant, fertile, wrinkle free and excited
about the posibilities life can offer.”18
SAFETY
The terms bioidentical and natural may imply safety to
consumers. A survey of 82 women interviewed at a compound-
ing pharmacy found that 74 had heard about natural
hormones and 37 used them.19 Half of those who had heard
about natural hormones believed that natural meant “not
synthetic/not man-made/no chemicals” and 45% thought the
term meant plant-derived. Only 11% agreed that natural
meant “identical to human hormones.” More than two thirds
(71.4%) of respondents believed that natural hormones had
fewer risks than pharmaceutical hormones.
Bioidentical hormones are identical to hormones used in
some commercial pharmaceutical preparations. Estradiol, for
example, is available in pills (including Estrace®, Gynodiol®,
and generics), transdermal delivery systems (Climara®, Alora®,
Estraderm®, Vivelle®, and generics), vaginal creams (Estrace®
and generics), and vaginal rings (Estring®) and Femring®).
Progesterone is available in capsules (Prometrium®, Solvay
Pharmaceuticals, Marietta, Ga, USA [marketed], manufacturer:
Schering Plough) and vaginal gels (Crinone®, Serono Laborato-
ries, Inc., Rockland, Mass, USA and Prochieve, Columbia
Laboratories, Livingston, NJ, USA). Ironically, the estrogen in
the best-selling hormone preparations Premarin®, PremPro®,
and Premphase® (Wyeth, Philadelphia, Pa, USA) is derived from
pregnant mare’s urine, an inarguably natural source.
Interest in bioidentical hormones appears to have increased
since 2002, when the estrogen–progestin arm of the NIH-funded
Women’s Health Initiative (WHI) was stopped because of harm.20
(the estrogen-only arm was stopped in 2004). In this definitive
randomized controlled trial (RCT) that included more than
26,000 women, neither estrogen21 nor estrogen–progestin com-
binations reduced cardiovascular risk.20,22,23 Both estrogen24
andestrogen–progestintherapy25 increasedstrokerisk;estrogen–
progestin therapy increased rates of breast cancer20 and demen-
tia.26,27Hormonetherapyincreasedtheriskof incontinence28and
improved quality of life only inwomenwith hot flashes.29
The WHI tested conjugated equine estrogens (with and
without medroxyprogesterone acetate), but no RCT to date
has shown a benefit for any estrogen on cardiovascular events.
Two RCTs have shown that estradiol, a natural hormone,
prevents neither heart attack22,23 nor stroke.30
Estriol, specifically, is believed by bioidentical hormone
proponents to decrease breast cancer risk. This belief is based
on several articles written in the 1970s by a researcher who
remained enthusiastic about estriol even after his only pub-
lished clinical study failed. Six of the 24 subjects with breast
cancer who took estriol developed metastases; two developed
endometrial hyperplasia.31 The researcher, however, never
made specific disease prevention claims about estriol.
Other evidence refutes the purported benignity of bioidenti-
cal estrogens on the breast. High levels of endogenous estradiol
and estrone are associated with increased breast cancer risk;32–37
estriol has also been implicated in increased risk.38 In breast
cancer cell lines, estriol stimulates breast cancer cell growthmore
than other estrogens.39 Breast tissue from women with breast
cancer, compared to women without breast cancer, contains
higher levels of estriol, estrone, and estradiol.40
Little information is available about long-term effects of
micronized progesterone. There is preliminary evidence from
E3N-EPIC, a large French cohort study of 98,997 women
followed up for a mean of 5.8 years, that hormone regimens
incorporating micronized progesterone rather than other pro-
gestogensmay be safer in terms of breast cancer risk.41 However,
this is an observational study, not an RCT, that included
hormone regimens rarely used in other countries. This study by
no means constitutes proof of a differential effect.
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ENDOMETRIAL EFFECTS OF TRANSDERMAL
PROGESTERONE CREAMS AND ESTRIOL
Women with intact uteri are prescribed estrogen with a
progestogen to oppose estrogen-induced endometrial hyper-
plasia and cancer. Bioidentical hormone proponents some-
times recommend topical progesterone cream instead of oral
progestin for this purpose. However, it is unclear whether
topical progesterone can effectively mitigate estrogen-induced
endometrial stimulation. Three studies have examined the
ability of progesterone to oppose estrogenic stimulation. The
longest study, which lasted for 48 weeks, found that transder-
mal cream containing 40 mg of progesterone could not
effectively oppose estradiol-induced endometrial stimulation.42
A 12-week study of a cream containing up to 64 mg of
progesterone found similar effects.43 The only study that found
that progesterone cream (1.5% or 4%, dosed by body weight)
effectively opposed estrogen lasted only 28 days, too short a
time to assess estrogenic effects.44 Five studies that measured
serum or plasma levels after topical progesterone treatment
have found progesterone levels <5 ng/mL (the minimum level
believed to induce a secretory endometrium).45–49 Only one
study found a progesterone cream equivalent to oral proges-
terone after measuring progesterone concentration in whole
blood50 (Table 1).
Although oral estriol preparations are an alternative treat-
ment for menopausal symptoms in the United States, estriol is
a commonly prescribed conventional drug in other countries51
and was often prescribed without a progestin. Although estriol
is far less potent than estradiol and rapidly metabolized, estriol
appears to stimulate proliferative changes identical to those
induced by more potent estrogens.52 Two Swedish studies
Table 1. Bioavailability Studies on Topical Progesterone Cream










Progesterone cream (1.5% or 4.0%, dosed
by weight)
Endometrial biopsies showed significant
decrease in endometrial proliferation scores
in both treatment groups, compared with
placebo and compared to baseline biopsies
taken 2 wks after estrogen treatment.
Placebo cream, each applied
topically twice daily
All subjects received conjugated











ProFemme cream (containing 16, 32, or
64 mg micronized progesterone), each for
latter 2 wks of each 4-wk treatment cycle
None of the 21 endometrial biopsies obtained
indicated a secretory endometrium. Serum
progesterone levels rose to 0.6–3.2 ng/mL.










Progestelle (6% progesterone cream
containing 40 mg progesterone/d)
Endometrial biopsies showed that mean
endometrial thickness increased significantly
from 3.3 to 5.5 mm. At 48 wks, out of 39
biopsies obtained, 2 showed endometrial
hyperplasia, and 10 demonstrated endometrial
proliferation. Median plasma progesterone
levels increased from 1.9 to 2.5 nmol/L.










Pro-Gest cream (40 mg twice daily) In a whole blood assay, progesterone levels
increased after both topical and oral progesterone.
No significant difference between groups; median
AUC (area under the curve) was 12.5 ng h−1 mL−1
after Pro-Gest and
10.5 ng h−1 mL−1 after oral progesterone.
Prometrium (micronized progesterone,













20 mg/g 1–2 g
Plasma progesterone increased significantly but
slightly in both treated groups, compared to the
placebo group (range 0.32–1.77 nmol/L in the
20-mg group, 0.59–3.53 nmol/L in the 40-mg
group). Salivary progesterone levels were high,
variable, and did not correlate with serum levels.
Compounded progesterone cream
(40 mg/g) 1–2 g
Placebo (treatments applied twice daily for








Progestelle cream (containing 40 mg
progesterone once daily)
Serum progesterone increased to 2.5–3.0 nmol/L
(with wide variation). No difference between












ProFemme cream (containing 64 mg
progesterone)
No change from baseline in serum progesterone
in either group 3 h after treatment. Salivary









Pro-Gest cream (containing 30 mg
progesterone daily) × 2 wks, then 30 mg
wice daily × 2 wks
Mean serum progesterone levels rose to 1.0–3.3
ng/mL.











One teaspoon of Pro-Gest cream or
placebo (each treatment applied twice-
daily ×10 d, with a 4-d washout period)
Median plasma progesterone levels after 10 d
were 2.9 nmol/L after Pro-Gest, compared to
9.5 nmol/L with oral progesterone.
Each subject then took Uterogestan (oral
progesterone 100 mg qam and
200 mg qpm × 5 d
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found that unopposed oral estriol (1–2 mg/day) was associated
with endometrial hyperplasia.53,54 Compared to nonusers, the
use of oral estriol doubled the risk of endometrial cancer;
5 years of oral estriol tripled the risk. Vaginal estriol did not
significantly increase risk.54 Although one recent study con-
cluded that estriol has a benign effect on the endometrium,55
the data presented show that estriol treatment was associated
with significant endometrial thickening and polyps, both
considered to be estrogenic effects.56
The FDA’s Guidance for Industry states, “other combinations
and dosage forms of estrogens and progestins were not studied
in the WHI clinical trials and, in the absence of comparable
data, these risks should be assumed to be similar.”57
SALIVARY HORMONE TESTS
Saliva testing for hormones has been promoted to individualize
the dosing of bioidentical hormone treatment. It is not clear how
best to correlate progesterone levels with endometrial effects,
but it is clear that salivary progesterone levels are unreliable.
Correlations between serum and salivary levels of reproductive
hormones vary by hormone tested, time of day, diet, and type of
assay.51 Also, serum levels may not reflect tissue levels.58
Hormone tests are not indicated for menopausal symptoms
because there is no correlation between hormone levels and
symptoms. Salivary tests may be used to persuade asymptom-
atic women to use hormones, and may encourage symptomatic
women to use higher doses than are necessary to treat
symptoms. This would be expected to result in an unfavorable
risk–benefit ratio. As Boothby et al.51 stated in an excellent
review, “Although attractive on the surface, individualized NHT
[natural hormone therapy] is an ill-conceived attempt to apply
pharmacokinetic principles to drugs that do not meet the
criteria for individualized dosing.”
DISCUSSION
Bioidentical hormones are an unusual form of alternative
medicine. Unlike dietary supplements, most orally adminis-
tered hormones require a physician’s prescription. Despite the
fact that these hormones are no more natural than (and in
many cases are identical to) commercially available drugs,
when formulated by a compounding pharmacy these prepara-
tions fall outside of the current realm of FDA regulation. No
reliable data support the claim that bioidentical hormones are
safer than other hormones, and natural, bioidentical, and
compounded preparations must be assumed to have the same
risks as commercial hormone preparations.
Commercial or compounded estrogen preparations should
be effective for treating hot flashes or vaginal dryness, and oral
micronized progesterone is acceptable as the progestogen
portion of menopausal hormone therapy. Any estrogen, in-
cluding estriol, should be opposed with an oral progestogen in
nonhysterectomized women. Whereas some progesterone
creams may provide some endometrial protection in some
women, studies to date are not reassuring. Progesterone
creams should not be relied upon to protect uterine endome-
trium from estrogen-induced stimulation. Oral progestogens
with known effects are preferred.
Any menopausal hormone therapy should be reserved for
women with bothersome symptoms, and used in the lowest
effective dose for as brief a period as possible. Whereas
compounded preparations may be useful for creating lower-
dose preparations of hormones, these preparations lack the
consistency and regulatory oversight required of commercial
hormonal drugs.
Adverse effects of hormones must be assumed to be drug
class effects until reliable clinical evidence proves otherwise.
Claims that the hormones present in compounded prescrip-
tions are safer than commercial pharmaceuticals can only be
made by those unfamiliar with or unwilling to accept scientific
data. Women who wish to use compounded hormones to treat
menopausal symptoms should be counseled that bioidentical
hormones have the same risks as conventional hormones.
Because hormones are readily absorbed through the skin,
the FDA should regulate transdermal hormone preparations
as drugs. In addition, the FDA should require compounding
pharmacies to provide patients with the same written infor-
mation required of commercial drugs with any compounded
prescriptions made with those drugs. To do otherwise risks the
health of consumers.
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